(Q43550651)

24 November 2017

0 references

Dofetilide: is the treatment worse than the disease? (English)

1 reference

24 November 2017

M R Lauer

1

1 reference

24 November 2017

language of work or name

English

0 references

publication date

1 March 2001

1 reference

Journal of the American College of Cardiology

24 November 2017

published in

1 reference

24 November 2017

volume

37

1 reference

24 November 2017

issue

4

1 reference

24 November 2017

page(s)

1106-1110

1 reference

Two components of cardiac delayed rectifier K+ current. Differential sensitivity to block by class III antiarrhythmic agents

24 November 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2801%2901146-9

7 January 2021

Electrophysiological and inotropic effects of H 234/09 (almokalant) in vitro: a comparison with two other novel IK blocking drugs, UK-68,798 (dofetilide) and E-4031

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2801%2901146-9

7 January 2021

Electropharmacology of dofetilide, a new class III agent, in anaesthetised dogs.

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2801%2901146-9

7 January 2021

Rate-dependent class III antiarrhythmic action, negative chronotropy, and positive inotropy of a novel Ik blocking drug, UK-68,798: potent in guinea pig but no effect in rat myocardium

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2801%2901146-9

7 January 2021

Clinical and electrophysiologic effects of intravenous dofetilide (UK-68,798), a new class III antiarrhythmic drug, in patients with angina pectoris

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2801%2901146-9

7 January 2021

Effects of the new class III antiarrhythmic drug dofetilide on the atrial and ventricular intracardiac monophasic action potential in patients with angina pectoris

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2801%2901146-9

7 January 2021

Dofetilide in patients with congestive heart failure and left ventricular dysfunction. Danish Investigations of Arrhythmia and Mortality on Dofetilide Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2801%2901146-9

7 January 2021

Dofetilide for the treatment of atrial fibrillation in patients with congestive heart failure

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2801%2901146-9

7 January 2021

Efficacy and safety of oral dofetilide in converting to and maintaining sinus rhythm in patients with chronic atrial fibrillation or atrial flutter: the symptomatic atrial fibrillation investigative research on dofetilide (SAFIRE-D) study

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2801%2901146-9

7 January 2021

Sotalol: An important new antiarrhythmic

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2801%2901146-9

7 January 2021

Polymorphous ventricular tachycardia: clinical characterization, therapy, and the QT interval

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2801%2901146-9

7 January 2021

Incidence and clinical features of the quinidine-associated long QT syndrome: implications for patient care

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2801%2901146-9

7 January 2021

Efficacy and safety of repeated intravenous doses of ibutilide for rapid conversion of atrial flutter or fibrillation. Ibutilide Repeat Dose Study Investigators

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2801%2901146-9

7 January 2021

Torsade de pointes due to quinidine: observations in 31 patients

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2801%2901146-9

7 January 2021

Pause-dependent polymorphic ventricular tachycardia during long-term treatment with dofetilide: a placebo-controlled, implantable cardioverter-defibrillator-based evaluation.

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2801%2901146-9

7 January 2021

Radiofrequency catheter ablation for atrial fibrillation

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2801%2901146-9

7 January 2021

Mortality and morbidity in patients receiving encainide, flecainide, or placebo. The Cardiac Arrhythmia Suppression Trial

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2801%2901146-9

7 January 2021

Effect of d-sotalol on mortality in patients with left ventricular dysfunction after recent and remote myocardial infarction. The SWORD Investigators. Survival With Oral d-Sotalol.

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2801%2901146-9

7 January 2021

Proarrhythmia with class III antiarrhythmic drugs: types, risks, and management

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2801%2901146-9

7 January 2021

A randomized, double-blind, placebo-controlled, dose-ranging study of dofetilide in patients with inducible sustained ventricular tachyarrhythmias

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2801%2901146-9

7 January 2021

Electrophysiologic profile and efficacy of intravenous dofetilide (UK-68,798), a new class III antiarrhythmic drug, in patients with sustained monomorphic ventricular tachycardia. Dofetilide Arrhythmia Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2801%2901146-9

7 January 2021

10.1016/S0735-1097(01)01146-9

Identifiers

DOI

1 reference

24 November 2017

1 reference